Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
NCT03072160Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Medullary Thyroid Cancer (MTC) (2 cohorts), sponsored by National Cancer Institute. Primary endpoints: Clinical Response at 2 years and Objective Response Rate at 2 years. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT03072160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072160.